Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RBP4 | P02753 | 2/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 6/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 5/20 | 0.34 |
| ▸ | PDE4A | P27815 | 3/20 | 0.34 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.34 |
| ▸ | GSK3A | P49840 | 3/20 | 0.33 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 2/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3954500 | 0.93 | RBP4 (0.39) | RBP4PDE10APDE4BPDE4DPDE4A | |
| SCHEMBL2748033 | 0.73 | DYRK1A (0.47) | PDE10ATGFBR1CDK2 | |
| SCHEMBL16972526 | 0.70 | PDE10A (0.41) | RBP4PDE10AMCHR1 | |
| SCHEMBL26186714 | 0.70 | PDE10A (0.41) | RBP4PDE10AMCHR1MAPT | |
| SCHEMBL446360 | 0.69 | PDE10A (0.38) | RBP4PDE10APDE4BPDE4DPDE4A | |
| SCHEMBL9935117 | 0.69 | RBP4 (0.32) | RBP4 | |
| SCHEMBL1744717 | 0.69 | RBP4 (0.32) | RBP4 | |
| SCHEMBL25658370 | 0.69 | RBP4 (0.32) | RBP4 | |
| SCHEMBL3122117 | 0.69 | PDE4A (0.34) | RBP4PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL26373813 | 0.69 | RBP4 (0.32) | RBP4PDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4262802-A1 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | Children's Hospital Medical Center (US) | 2023-10-25 | — | — | EP | disclosed |
| CN-116887834-A | Polycyclic IRAK and flt3 inhibiting compounds and uses thereof | 儿童医院医学中心 | 2023-10-13 | — | — | CN | disclosed |
| WO-2022132936-A1 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2022-06-23 | — | — | WO | disclosed |
| US-10669279-B2 | Imidazopyridazine compounds | PFIZER INC. (US) | 2020-06-02 | — | — | US | disclosed |
| US-20190322674-A1 | IMIDAZOPYRIDAZINE COMPOUNDS | PFIZER (US) | 2019-10-24 | — | — | US | disclosed |
| US-20180346475-A1 | Imidazopyridazine Compounds | PFIZER INC. (US) | 2018-12-06 | — | — | US | disclosed |
| EP-2740730-B1 | DIBENZOOXEPIN DERIVATIVE | KYOWA HAKKO KIRIN CO LTD (JP) | 2016-11-16 | — | — | EP | disclosed |
| US-8969345-B2 | Dibenzooxepin derivative | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2015-03-03 | — | — | US | disclosed |
| US-20140163008-A1 | DIBENZOOXEPIN DERIVATIVE | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2014-06-12 | — | — | US | disclosed |
| EP-2740730-A1 | DIBENZOOXEPIN DERIVATIVE | Kyowa Hakko Kirin Co., Ltd. (JP) | 2014-06-11 | — | — | EP | disclosed |
| US-8183241-B2 | 2-oxo-1-pyrrolidine derivatives | UCB PHARMA, S.A. (BE) | 2012-05-22 | — | — | US | disclosed |
| US-20090156607-A1 | 2-OXO-1-PYRROLIDINE DERIVATIVES | UCB, S.A. (BE) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180346475-A1 | Imidazopyridazine Compounds | CYP3A5, QDPR, CYP3A7 | RBP4 3540/4885PDE10A 827/4885PDE4B 206/4885 |
| US-20190322674-A1 | IMIDAZOPYRIDAZINE COMPOUNDS | CYP3A5, QDPR, CYP3A7 | RBP4 3540/4885PDE10A 827/4885PDE4B 206/4885 |
| US-10669279-B2 | Imidazopyridazine compounds | CYP3A5, QDPR, CYP3A7 | RBP4 3540/4885PDE10A 827/4885PDE4B 206/4885 |
| US-20090156607-A1 | 2-OXO-1-PYRROLIDINE DERIVATIVES | OPRD1, PPOX, CYP2D6 | RBP4 4068/4885PDE10A 1257/4885PDE4B 632/4885 |
| US-20140163008-A1 | DIBENZOOXEPIN DERIVATIVE | PPARA, PPARG, PPARD | RBP4 18/4885PDE10A 3316/4885PDE4B 1267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.